Research summary ·
Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review compared treatments for functional hypogonadism in men with obesity. It pooled trials in a network meta-analysis. Trials tested structured lifestyle therapy (SLT) and testosterone replacement therapy (TRT). Others tested restoring the body's own testosterone (ETR) and therapy based on glucagon-like peptide-1. One more was TRT plus SLT. The authors also rated how sure they could be of each result.
What they found
The trials had 1899 participants. TRT plus SLT gave the largest rise in total testosterone. It also raised scores for erectile function. No treatment clearly cut glycated hemoglobin. TRT cut waist size. It raised lean mass and hematocrit. ETR and TRT plus SLT also raised lean mass. Adverse events did not differ significantly.
What it means for patients
The authors say each treatment had different effects on different outcomes. They say no one strategy was always better. They say the findings should guide individual treatment choices, not a final ranking.
Why it is not certain yet
For many comparisons, confidence in the evidence was low or very low. The trials differed in people, treatment plans and follow-up time. The authors say longer head-to-head trials are needed to confirm the findings.
Source
Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.
PubMed · PMID 42704281We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Male hypogonadism publications